case_images: PMC9597015_01
case_images: Immunophenotype of leukemia cells by FCM before and after combination therapy
  with daratumumab. (A) Before daratumumab: Malignant B lymphocytes
  characterized as CD19+CD22+CD34+CD10dim and CD20-CD38- by FCM. (B) After
  daratumumab: She achieved CR with CD19-CD22-CD34+CD10-CD20-CD38- by FCM.
  FCM: flow cytometry; CR: complete remission.
case_images: 10.1177_09636897221132502-fig1.jpg
case_images: PMC9597015_01_10.1177_09636897221132502-fig1.jpg
case_images: fig1-09636897221132502
case_images: ALL. After one course of VDCLP (vincristine, daunorubicin, cyclophosphamide, l-asparaginase, and prednisolone), two cycles of CAM (cyclophosphamide, cytarabine, and 6-mercaptopurine), and two courses of high-dose methotrexate combined with venetoclax chemotherapy, her disease did not achieve CR with 30.36% leukemia cells in the bone marrow (BM) by flow cytometry (FCM) (Fig. 1A). After one cycle of combination therapy, she achieved CR with a significant decrease in DSA levels (Fig. 1B, Table 1).